Confidential buy-side & sell-side mandates in UK medicinal cannabis.
Medicexum runs a discreet introductions process for founders, owners and investors transacting in UK medicinal cannabis, CBD and adjacent regulated sectors. No mandate is named publicly. Nothing identifying is released without signed NDA, non-circumvent and introducer-fee agreements in place. Our network spans UK operators, Canadian Licensed Producers and North American capital.
Identity withheld until NCNDA + IFA signed
No company names, financials or licences are shared until a mutual NDA, non-circumvent and introducer fee agreement are executed by all parties.
Qualification-gated access
Buyers complete a regulated-status and source-of-funds declaration before any blind teaser is released. Sellers approve every party a teaser is shown to.
Staged disclosure
Blind teaser → CIM in a permissioned, watermarked data room → management meeting under LOI exclusivity. Each step requires written interest.
A transatlantic bridge — sourcing and capital.
Canadian sourcing partners
Working relationships with established Canadian Licensed Producers supplying EU-GMP-aligned medicinal cannabis into the UK. Used to support buyer mandates needing product and sell-side clients closing supply gaps. Partners are never named publicly.
North American capital
Active dialogue with US-based investors and family offices evaluating UK medicinal cannabis opportunities. Qualified mandates can be introduced discreetly to North American capital alongside UK buyers, under the same NCNDA framework.
How a Medicexum introduction runs.
- Step 1 Qualification (regulated status, jurisdiction, ticket size, source of funds).
- Step 2 Mutual NCNDA + Introducer Fee Agreement executed via DocuSign.
- Step 3 Blind 1-page teaser shared (sector, region, revenue band, licences — no name).
- Step 4 CIM and data room access in a permissioned, watermarked VDR after written interest.
- Step 5 Management meetings under LOI exclusivity.